Coloplast A/S Class B COLO_B

The global ostomy dressings market is projected to grow from USD 3.80 billion in 2026 to USD 4.73 billion by 2031, at a 4.4% CAGR. Growth is driven by rising colorectal cancer and inflammatory bowel disease cases, aging populations, improved peristomal skin care awareness, and expanding home care services. Skin barrier rings will record the fastest product growth, while Asia Pacific will be the fastest-growing region. Key companies include Coloplast, ConvaTec, Hollister, B. Braun, Solventum, and

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel. +45 4911 1800 For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Kristine Husted MunkSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: [email protected]

Coloplast has been informed that the Danish Financial Supervisory Authority (FSA) has today announced that it has notified Niels Peter Louis-Hansen that it has granted an exemption from the obligation to make a mandatory takeover offer to the shareholders of Coloplast A/S in connection with the contemplated transfer of a controlling indirect ownership interest in Coloplast A/S from NPLH Holding ApS to a non-profit foundation. Reference is made to the Danish Financial Supervisory Authority’s prio

Coloplast AS (CLPBF) delivers 6% organic revenue growth and 5% EBIT growth in constant currencies, while navigating US reimbursement headwinds and China inventory adjustments.

Interim financial results, 9M 2025/261 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex. China and Interventional Urology; continued reimbursement-related challenges in Biologics. Reported revenue in DKK also grew 6%, as currencies had a net neutral impact. Return on invested capital after tax before special items was 15%.• Organic growth rates by business area: Ostomy Care 5%, Continence Ca

Coloplast announces changes to Executive Leadership Team Today, Coloplast announces two changes to the company’s Executive Leadership Team (ELT). The changes strengthen the leadership of Coloplast’s people & culture agenda and introduce a change to the Wound & Tissue Repair business setup. Coloplast appoints Amanda Rajkumar as Chief People Officer Effective September 1, Amanda Rajkumar will join Coloplast and the Executive Leadership Team as Chief People Officer. The appointment reflects Colopla

The Savile Row home of luxury menswear tailor Gieves & Hawkes has been snapped up for £31m by a Danish catheter billionaire.

LONDON, June 11, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10.

Investing.com -- Kepler Cheuvreux initiated coverage of Danish medtech company Coloplast with a “buy” rating and a target price of DKK482.

The European stock market has experienced a mixed performance recently, with the pan-European STOXX Europe 600 Index showing modest gains amid easing geopolitical tensions and strong corporate earnings. However, concerns over potential U.S. tariffs on EU goods have introduced some volatility into the market landscape. In such an environment, identifying stocks that are potentially undervalued can be crucial for investors looking to capitalize on discrepancies between a company's intrinsic...

Global markets have recently shown resilience, with U.S. equity markets rallying on the back of strong corporate earnings and a robust labor market, while European indices experienced modest gains amid easing geopolitical tensions. Despite these positive trends, certain stocks remain undervalued relative to their intrinsic value estimates, presenting potential opportunities for investors who focus on fundamentals and long-term growth prospects.

As the pan-European STOXX Europe 600 Index concluded a turbulent week with modest gains, investor sentiment was buoyed by easing geopolitical tensions and robust corporate earnings across the region. However, concerns over potential U.S. tariffs on EU goods introduced some volatility into the markets. In this environment, identifying stocks that may be priced below their intrinsic value estimates can offer opportunities for investors seeking to capitalize on market inefficiencies and strong...

2025/26Interim financial results, H1 2025/261 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging quarter in Wound & Tissue Repair. Reported revenue in DKK grew 2%, with 4%-points negative impact from currencies. Return on invested capital after tax before special items was 15%. • Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice &

In recent weeks, the European market has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, although concerns over potential U.S. tariffs on EU goods have weighed on investor sentiment. As the European Central Bank signals potential rate hikes to combat rising inflation, investors are increasingly focused on identifying stocks that may be undervalued relative to their intrinsic value amidst these complex economic conditions.

The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...

As European markets navigate a landscape marked by stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index remains relatively stable, with corporate earnings showing positive momentum. Amid these conditions, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value in a market where economic sentiment has dipped to its lowest since 2020.

As the European market navigates through a landscape marked by stable interest rates and geopolitical uncertainties, the pan-European STOXX Europe 600 Index has managed to maintain a steady course, reflecting cautious optimism amid positive earnings momentum. In this environment, identifying potentially undervalued stocks becomes crucial for investors seeking opportunities that may offer value relative to their estimated worth.

As the pan-European STOXX Europe 600 Index ended the week broadly flat amid stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing potential opportunities in undervalued stocks. In this context, identifying stocks that might be priced below their estimated value can be crucial for those looking to capitalize on positive earnings momentum despite broader economic uncertainties.